IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm® technology platform.
IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. Established for the VersaFilm® technology platform, IntelGenx’s state-of-the art manufacturing facility supports lab-scale-to-pilot and commercial-scale production, offering full-service capabilities to our clients.
RSI AT 77. MACD … bullish … recent spike can indicate a catalyst is imminent!!!
Daily volume on the rise … IGX traded over 680 000 shares since Sept 2
Support: S2; $ 0.75 S1; $ 0.85 Resistance: R1; $ 0.94 R2; $ 1.00
PLEASE DO YOUR DUE DILIGENCE
This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this report.
Mi3 Communication Financière Inc. | 590 Jacques Lavigne Suite 402 | Ste-Thérèse, QC J7E 0A8 Canada
Copyright © 2018 Mi3 Communication Financière Inc.